RADIANT: CD101 vs Standard of Care in Subjects With Acute Vaginal Yeast Infections

NCT02733432 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

126

Enrollment

INDUSTRY

Sponsor class

Conditions

Candidiasis, Vulvovaginal
Mycoses
Yeast Infection
Moniliasis, Vulvovaginal
Vaginitis, Monilial

Interventions

DRUG: CD101 Vaginal Gel (3%)
DRUG: CD101 External gel (1%)
DRUG: CD101 Vaginal Ointment (6%)
DRUG: CD101 External ointment (1%)
DRUG: Fluconazole

Sponsor

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)